LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
University of Paris-Saclay
Gif-sur-Yvette, FranciaPublicaciones en colaboración con investigadores/as de University of Paris-Saclay (11)
2024
-
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191
2023
-
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
2021
-
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969
-
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
European Journal of Cancer, Vol. 151, pp. 211-220
2020
-
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Radiotherapy and Oncology, Vol. 149, pp. 84-88
2019
-
Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119
-
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Radiotherapy and Oncology, Vol. 133, pp. 163-166
2017
-
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Clinical Lung Cancer
-
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
The Lancet, Vol. 389, Núm. 10072, pp. 917-929
2014
-
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Clinical Cancer Research, Vol. 20, Núm. 16, pp. 4251-4261